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Abstract
Background: The aim of this study was to determine the prevalence of human papillomavirus (HPV) and 15
species that cause sexually transmitted infections (STIs) in negative cytology. In addition, we compared the
diagnostic performance of multiplex polymerase chain reaction (PCR) with widely available techniques used to
detect HPV.
Methods: We recruited 235 women of reproductive age who had negative cytology findings in a liquid-based
cervical smear. STIs were identified by multiplex PCR, and HPV genotypes by multiplex PCR, hybrid capture 2, and
DNA microaray; discordant results were analyzed by direct sequencing.
Results: Approximately 96.6% of patients with negative cytology results were positive for pathogens that cause
STIs. The pathogens most frequently detected were Gardnerella vaginalis, Ureaplasma urealyticum. The incidence of
HPV in negative cytology was 23.3%. Low-risk HPV infection was significantly correlated with Chalmaydia
trachomatis, and high-risk HPV infection was significantly correlated with Group b streptococcus. The analytical
sensitivities of the multiplex PCR and DNA microarray were higher than 80%, and the analytical specificity was
nearly 100% for all tests.
Conclusions: Multiplex PCR yielded results that most of patients with negative cytology were positive for
pathogens that cause STIs, and were more similar to that of DNA microarray, than that of hybrid capture 2 in
terms of analytical sensitivity and prediction value of HPV infection.
Background
Sexually transmitted diseases (STDs) are fairly common
in people of reproductive age; more than 50% of new
STD infections occur in adolescents. However, only 50%
to 80% of reportable STDs that occur in the United
States are actually reported [1]. Testing for STDs can
result in negative cytology, that is, laboratory test results
that revealed reactive cellular change (RCC) or atypical
squamous cells of undetermined significance (ASCUS).
RCC or ASCUS is routinely screened for, but they are
not associated with neoplasms or preneoplastic stages
known as squamous intraepithelial lesions (SILs). RCCs
are cytological alterations related to inflammation or
irritation but, whether subtle or marked, are typically
not associated with human papillomavirus (HPV) infec-
tion. Common features of RCCs include the formation
of small perinuclear halos, mild nuclear enlargement or
nuclear degeneration, hyperchromasia, cytoplasmic
pseudokeratinization, cytoplasmic vacuolization, and
notably a background of inflammation. The abnormal
cytology of ASCUS can usually be distinguished from
RCC, but does not meet all criteria of HPV-infected koi-
locytes [2].
With the exception of a few organisms that cause sexu-
ally transmitted infections (STIs) such as trichomoniasis
or candidiasis, most inflammatory agents are only rarely
recognized under the microscope and usually produce
nonspecific cytopathic effects. For example, bacterial
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any medium, provided the original work is properly cited.vaginosis (BV) is a leading cause of abnormal vaginal dis-
charge as a sequel of gynecologic conditions, including
endometritis, pelvic inflammatory disease (PID), post-
surgical abortion, post-hysterectomy infection, and cervi-
cal intraepithelial neoplasia [3]. However, few attempts
have been made to identify the etiologic organisms of
BV, and diagnoses have relied only on the presence of
common “clue cells” detected in cervical swabs [4,5]. The
prime manifestation of BV constitutes a massive micro-
ecologic alteration of vaginal flora characterized by
decreased Lactobacillus spp., logarithmically-increased
Gardnerella vaginalis, and the presence of potentially
pathogenic bacteria, including Bacteroides, Peptococcus,
Mobiliuncus, Ureaplasma urealyticum,a n dMycoplasma
spp. Mycoplasma spp.a n dU. urealyticum are most fre-
quently detected in the vaginal tract [6], and are strongly
associated with infertility, intra-amniotic infection, post-
partum infection, and pelvici n f l a m m a t o r yd i s e a s e( P I D )
[1-5]. The multiple strains of Mycoplasma are the only
cell wall-deficient, membrane-bound organisms capable
of independent self-replication: they include Mycoplasma
hominis, M. genitalium, M. primatum, M. spermatophi-
lum, and M. penetrans [7,8].
Despite the fact that many pathogens are not detected
by Gram stain, Gram-stained vaginal secretions are still
accepted as the diagnostic gold-standard, rather than
the culture of secretions. With the advent of advanced
techniques such as those based on liquid-based cytology
[9-13], it is now feasible to accurately and efficiently
identify microorganisms in cervicovaginal swab speci-
mens of asymptomatic patients with multiplex PCR or
DNA chip. Although detection of infectious organisms
is not the primary goal of cervical cytology, it can be an
important component of screening in asymptomatic
patients or subtle disease. We aimed to estimate the
incidence of STIs in healthy women of reproductive age
with negative cytologic findings by multiplex PCR and
find any correlation of HPV infection with specific
pathogens.
High-throughput technology including hybrid cap-
ture 2 (HC2) and DNA microarray has been currently
adopted to detect HPV [14]. HC2 is a relatively easy
method with high screening power, but it is unable to
genotype or excludes low-risk HPV types. DNA micro-
array can identify specific genotypes, and can also
detect co-infection in a single sample, but is labor-
intensive. Despite widely available high-throughput
technology for the detection of microbes or HPV, few
studies of STDs and HPV with high fidelity data exist
due to lack of a gold standard. We therefore designed
multiplex PCR assays to compare with the available
methods of HC2 and HPV DNA microarray, and ana-
lyzed discordant results by direct sequencing.
Methods
A total of 235 married and sexually active women (mean
age of 37.9 y; ages range 21 to 48 years) were recruited
by the Department of cytopathology of Yonsei Univer-
sity College of Medicine for this study. Specimens col-
lected from cervical liquid-based cytology medium were
negative for intraepithelial lesions. Participants had no
clinical STD symptoms that required a clinical visit, no
history of STDs, and no abnormal Papanicolau tests
(Pap smear) results. We also excluded patients with SIL
or carcinoma, postmenopausal women, or those with
previous operative or therapeutic history related to
gynecologic disease. The study protocol was approved
by the local institutional review board, and written
informed consent was obtained from all participants.
Multiplex-PCR for STI
Pretreatment and DNA Extraction of cervicovaginal swab
specimens
Cervix swab samples were collected from the posterior
fornix and lavaged with 5 mL of sterile phosphate-buffered
saline (PBS pH 7.4). PreservCyt specimens were tested by
Seeplex® STI Master ACE Detection (Seegene, Seoul,
Korea) or Seeplex® HPV4A ACE Screening (Seegene)
within 1 month of collection. PreservCyt transport med-
ium containing endocervical cells was vortexed vigorously,
and 1-mL samples were transferred into 1.5-mL polypro-
pylene tubes, each containing 1 mL of PreservCyt trans-
port medium. The tubes were centrifuged at 13,000 × g
for 15 min at 20°C. Supernatants were discarded, and each
cellular pellet was suspended in 200 μL of PBS. DNA was
purified from these samples using the QIAamp DNA Mini
Kit according to the manufacturers’ instructions (Qiagen,
Hilden, Germany). The quality and quantity of purified
DNA was measured by spectrophotometry.
Multiplex PCR
Four primer sets were tested by STI multiplex PCR: See-
plex® STI Master Panel 1, 2, 3, and HPV4A ACE Screen-
ing. Panel 1 comprised of Neisseria gonorrhoeae (NG),
Mycoplasma hominis (MH), Chlamydia trachomatis
(CT), Ureaplasma urealyticum (UU),a n dM. genitalium
(MG). Panel 2 comprised Trichomonas vaginalis (TV),
Gardenerella vaginalis (GV), Bacteroides fragilis (BF),
Mobiluncus curtisii (MC),a n dM. mulieris (MM).P a n e l
3 comprised Candida glabrata (CG), C. tropicalis (CT1),
C. parapsilosis (CP), Group b-s t r e p t o c o c c u s(GBS), and
C. albicans (CA). Primers were designed such amplicon
sizes differed sufficiently to be distinguished from each
other; they ranged from 212 bp (UU) to 635 bp (CG)
and the internal control was 981 bp. Optimized multi-
plex PCR was performed in 20 μL reactions containing
DNA template, primer mixture (final concentration of
each primer, 3 pmole), 2× Master mix (Seegene, Korea)
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Page 2 of 8and 30 μg/mL of 8-methoxypsoralen (MOP), which pre-
vents contaminating DNAs from being amplified. PCR
amplification was performed in an Applied Biosystem
9700 thermal cycler (Perkin-Elmer, Boston, MA, USA)
with the following conditions: 94°C for 15 min, followed
by 40 cycles of 94°C for 30 sec, 63°C for 1.5 min (or
60 °C for 1.5 min for HPV4A ACE Screening), and 72°C
for 1.5 min; and final extension at 72 °C for 10 min. A
DNA plasmid was added to the PCR reaction mixtures
as an internal control to be co-amplified with the target
DNAs collected from the clinical specimens. Sterile
deionized water was included as a negative control in
each batch of PCR reactions. Target organisms, target
genes, accession numbers, and expected amplicon sizes
are summarized in Additional File 1.
Multiplex-PCR-
HPV was detected with the Seeplex® HPV4A ACE
screening kit for 14 HR-HPV types (31, 33, 35, 39, 45,
Figure 1 Sexually transmitted infection and human papillomavirus (HPV) multiplex PCR. Representative data of multiplex PCR with four
multiplex primer mixes: Seeplex® STI Master Panel 1 (MP1), 2 (MP2), 3 (MP3) and HPV4A ACE Screening. Panel 1 (B31) primers were designed so
that amplicons were different sizes: 214 bp (NG), 253 bp (MG), 348 bp (CT1), 435 bp (UU), 502 bp (MH), and 800 bp (internal control). Panel 2
(B32) amplicons were 155 bp (MM), 197 bp (MC), 343 bp (BF), 509 bp (GV), and 647 bp (TV).
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Page 3 of 851, 52, 56, 58, 59, 66, 67, 68, and 70) and 5 LR-HPV-
types (6, 11, 42, 43 and 44). In addition individual geno-
typing of HPV-16 and HPV-18 was performed with
different multiplex primer mixtures.
Hybrid capture 2 (HC2)
HC2 HPV test (Digene, Gaithersburg, MD) was per-
formed according to the manufacturer’s instructions to
detect HPV, starting from 4 mL of liquid cytology speci-
mens. The HC2-13 HR probe cocktail detects HPV
types-16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and
68. Relative light unit/cut-off ratio between 1 and 2.5
relative light units was used as the threshold for a posi-
tive result.
HPV Microarray
We used an HPV genotyping DNA microarray (Biocore
Ltd, Korea, Seoul) with multiple oligonucleotide probes
of L1 sequence of 26 types of HPV (HR: 16,18, 26, 31,
33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 69, 73 and 53;
LR: 70, 6, 11, 32, 34, 40, 42, 43, 44, 54, 55, 57, 61 and
62). L1 consensus PCR products were hybridized to the
probes on the microarray, and HPV genotypes were
identified with a fluorescence scanner (GenPix 4000B,
Axon Instruments Inc, CA) with a 532 nm laser for
excitation of Cy3.
DNA sequencing and cloning
Discrepant results among the HC2, DNA microarray, and
Seeplex® HPV4A ACE screening kit results were resolved
by sequencing with the PGMY09/PGMY11 primer sets.
PCR reactions (20 μL) were performed with 2 μLt e m -
plate DNA, 1 μM of each primer, and 2x Master mix
(Seegene, Korea). PCR amplification was carried out with
an Applied Biosystem 9700 thermal cycler (Perkin-
Elmer) with the following parameters: 94°C for 15 min
followed by 40 cycles of 94°C for 30 sec, 55°C for 1 min,
and 72°C for 1 min, and a final extension at 72°C for
10 min. The entire volume of each PCR reaction was run
on a 2% agarose/1× Tris-acetate-EDTA gel containing
ethidium bromide. The 465-bp bands amplified by the
PGMY09/PGMY11 primers were excised and transferred
to 1.5-mL tubes. DNA was extracted with the QiaexII gel
extraction system (Qiagen, Valencia, CA) and eluted with
20 μL Tris-EDTA buffer. The products were ligated into
the pGEM-T Easy vector (Promega, Madison, WI), trans-
formed into chemically-competent JM109 cells, and pla-
ted onto two Luria-Bertani (LB) plates containing
ampicillin, isopropyl-D-thiogalactopyranoside, and
5-bromo-4-chloro-3-indolyl-D-galactopyranoside. DNA
was extracted from the white colonies with the Qiaprep
Spin kit (Qiagen) and sequenced with the ABI Big Dye
Terminator v3.1 cycle sequencing kit and an ABI 377
sequencer (Applied Biosystems, Foster City, CA).
Sequences were trimmed to exclude the amplification
primer and vector sequences, and the resulting fragments
were analyzed by BLAST http://www.ncbi.nlm.nih.gov/
blast. The top hit for each sequence was listed as the
genotype.
Statistical Analysis
The agreement rate of kappa value with respect to a
quantitative measure of agreement between assay
methods was calculated. The sensitivity of the HPV
multiplex PCR, HC2 or DNA microarray relative to
DNA direct sequencing is the proportion of positive
samples in each assay among sequencing positive sam-
ples, and the specificity is the proportion of negative
samples in each assay among those negative samples in
direct sequencing. The positive predictive value is the
proportion of positive samples in DNA direct sequen-
cing, among those positive samples in each assay, and
the negative predictive value is the proportion of nega-
tive samples in sequencing among those negative in
each assay.
Results
Prevalence of STIs
The overall prevalence of STIs in cervicovaginal sam-
ples of negative cytology, which was not clinically
presented with BV, was 97.9% (230/235). Most patients
of 84.9% (202/230) were co-infected by more than
two microbes, whereas twenty-eight specimens were
infected by a single agent (Fig. 1). Table 1 is an exam-
ple to interpret data shown in Fig. 1 Most common
agents we detected were GV found in 88.1% of the
samples (207/235), UU in 63.0% (148/235), and GBS in
26.4% (62/235). The most frequently co-infected
organism was observed in MH infections, which was
commonly observed with UU (p = 0.000), MM (p =
0.000), MC (p = 0.000), and CT (p = 0.009). In addi-
tion, GV and MC (p = 0.014), MC and MM (p =
0.003), MG and CA (p = 0.006), and TV and GBS (p =
0.011) were similarly detected in the same samples.
HPV infection status
The incidence of HPV in negative cytology varied
according to the assay used: multiplex-PCR, 24.7% (58/
235); HC2, 21.3% (50/235); HPV chip, 22.6% (53/235).
The HPV types which were most often detected
included HPV-16 (PCR, 20.7%; DNA Chip, 26.4%) and
HPV-18 (PCR, 8.6%; DNA chip, 11.3%). Less commonly
detected HPV types included 51, 58, and 33 in the HR
group, and 70 and 6 in the LR group. Eighteen LR-HPV
types were detected by PCR (31.0%), eight by DNA
microarray (15.1%), and 11 by direct sequencing. Infec-
tion with multiple genotypes was detected in 13 speci-
mens (22.3%) by PCR and 14 specimens (26.4%) by
DNA microarray.
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Microarray
Overall, there are good agreements between methods to
detect HPV, and multiplex PCR showed the highest agree-
ment ratio with relation to direct sequencing (PCR vs.
sequence, Kappa = 0.8558; HC2 vs. sequence, Kappa =
0.8156; Chip vs. sequence, Kappa = 0.8539; PCR vs. HC2,
Kappa = 0.7179; PCR vs. Chip, Kappa = 0.8082; HC2 with
chip, Kappa = 0.7915;).
Because HC2 detects only HR group, 11 specimens
with LR-HPV infection were excluded in the analytic
sensitivity/specificity. The results of 25 of 235 specimens
(10.6%) were discordant among methods; therefore
these specimens were analyzed by direct sequencing.
DNA chip produced more false negative results than
HPV multiplex PCR and HC2 did (Table 2).
Performance characteristics of the diagnostic test are
shown in Table 3. Positive predictive values associated
with multiplex PCR and microarray were greater than
90%; the negative predictive value and accuracy rates
were greater than 95%. HPV multiplex PCR and DNA
microarray methods showed analytical sensitivities
greater than 85%, and analytical specificity was nearly
100% with all methods. The area under the curve
(AUC) was the highest for multiplex PCR at 0.922.
Receiver operating characteristics (ROC) are shown in
Fig. 2. However, there were no statistically significant
differences between the three methods tested.
Analysis of the correlation between STIs and HPV
infection
Specimens positive for LR-HPV infection were frequently
co-infected with C. trachomatis (4/18 HPV LR+ [22.2%];
p = 0.049), whereas those with HR-HPV were frequently
detected with GBS (6/37 HPV HR+ [16.2%]; p = 0.016).
Discussion
Reports of the incidence of STIs in asymptomatic
women are not currently available, because of few
attempts to recognize STI species despite advanced
techniques based on liquid-based cytology [9-13].
We found that the overwhelming majority of patients
with negative cytologic findings were positive for at least
one STI (97.9%); many were positive for multiple infec-
tious agents (84.9%). These results are surprising in that
we did not observe high rates of infection with microbes
that are typically widespread, such as N. gonorrhea and
C.trachomatis [10,13]. In more than 25% of the samples,
we detected microbes that cause asymptomatic, dormant
non-gonococcal and non-chlamydial infections, such as
G. vaginalis, U. urealyticum, Group b streptococcus,a n d
M. hominis. Microbes detected in less than 2% of the
specimens were CT-1, NG, and C. parapsilosis (CP) [13].
MH was often detected in the same sample with other
microbes, such as UU, M. mulieris (MM), M. curtisii
(MC),a n dCT. However, co-infection of multiple myco-
plasma strains has rarely been reported [15].
Table 1 Interpretation of data shown in Figure 1
Sample # MP1 MP2 MP3 HPV4AACE
1 M. hominis, U urealyticum/parvum G. vaginalis, B fragilis,
M. curtisii
C. tropicalis HRC
2 M. hominis, C. trachomatis G. vaginalis, M. curtisii - HPV-16
3 M. hominis, U urealyticum/parvum, M. genitlaium G. vaginalis, M. curtisii,
M. mulieris
GBS HPV-16
4 M. hominis, C. trachomatis,
U urealyticum/parvum
T. vaginalis, G. valginalis C. glabrata HPV-16, HPV 6/11
5 U urealyticum/parvum - C. parapsilosis HRC
6 M. hominis, C. trachomatis,
U urealyticum/parvum
G. vaginalis - HRC
7 - G. vaginalis, M. curtisii,
M. mulieris
C. glabrata HRC, HPV-6/11
8 C. trachomatis, U urealyticum/parvum G. vaginalis, M. mulieris C. albicans HPV-16, HRC
9 C. trachomatis, U urealyticum/parvum - GBS HRC, HPV-18
10 M. hominis, U urealyticum/parvum, M. genitalium - GBS HPV-16
11 - T. vaginalis, G. vaginalis,
B. fragilis
C. albicans HRC, HPV-18
12 N. gonorrhoeae T. vaginalis, G. vaginalis C. glabrata HPV-18
HRC: HPV high-risk common 11 types.
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infection, this increased risk of HPV infection in
patients with STIs was expected. Studies of women visit-
ing STD clinics have reported a greater prevalence of
HPV infection in this group than in the general popula-
tion [16,17]. In one study, approximately half of the
women evaluated at an STD clinic were infected with
genital HPV, including HPV types-16, 83, 56, 52, and 59
(HR group) and 66 (LR group) [16]. In the present
study of 235 asymptomatic women who had negative
cytology results, we found that approximately 20% were
infected with HPV. Using a genotyping microarray or
grouping multiplex PCR, the most common HR types
we detected were HPV types-16, 18, 51, 58, and 33, and
the most common LR type was HPV-70. Epidemiologic
data concerning HPV-types differ based on the method
of detection used and the target samples. Multiple infec-
tions with more than two different HPV genotypes were
found in 22% to 26% of the specimens, and HPV-16 was
most detected (50%).
Specimens infected with LR-HPV were frequently co-
infected with CT, whereas those with HR-HPV were
coinfected with GBS. The fact that CT associates with
LR-HPV rather than HR-HPV suggests that CT is less
likely to contribute to cervical intraepithelial neoplasia
or squamous cell carcinoma. Previous reports suggested
that coinfection with CT and HPV is common in
ASCUS and could contribute to the development of
intraepithelial lesions [18-24]. It is possible that the
modulation of cervical immune responses in response to
Table 2 Comparison of PCR, HC2, and Chip methods in 25 discordant samples
PCR HC2 Chip Sequence False + False −
1 LR N N N PCR
3 LR N** N 70 PCR
1* Chip
4 N HR N 53 HC2
2* PCR/Chip
5 HR HR N 66 HC2
3* Chip
6 HR HR N 54 PCR/HC2 Chip
7 LR HR N 11 HC2 Chip
8 N HR OTHER 83 HC2
4* PCR
4*
9 N HR OTHER 52 Chip: mistyping PCR
10 N HR OTHER N HC2/Chip
11 N HR N 39 PCR/Chip
12 HR N** 70 70 PCR
13 N HR 16 16 PCR
14 HR N 51 51 HC2
15 HR N** 11 11 PCR
16 HR N** 70 70 PCR
17 N HR 16+39 16+39 HC2
18 N HR 54 54 HC2
5* PCR
5*
19 N HR N N HC2
20 HR HR 70 70 PCR HC2
21 N HR N N HC2
22 N HR other N HC2/Chip
23 18+HR N 18+70 18+70 HC2
24 HR+LR N (equivocal) 73+43 73+43 HC2
25 HR N 51 51 HC2
PCR (20 types; 18 HR types+2 LR types): 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, and 82 + 6 and 11.
HC2: (13 HR types) 16,18,31,33,35,39,45,51,52,56,58,59, and 68.
Chip (26 types; 18 HR types+8 LR types): 16,18, 26, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, 69, 73, 53 and LR: 70, 6, 11, 32, 34, 40, 42, 43, 44, 54, 55, 57, 61, 62.
1*: PCR LR does not cover HPV-70 type.
2*: HC2 HR does not cover HPV-53 type.
3*: HC2 HR does not cover HPV-66 type.
4*: HC2 and PCR PR do not cover HPV-83 type.
5*: PCR LR does not cover HPV-54 type.
6*: PCR LR does not cover HPV-67 type.
**: HR2 was not considered in this analysis because HR2 excludes LR HPV types.
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and suggesting that CT infection with HPV persistence
i sn o tac o i n c i d e n c e[ 2 0 ] .L i k e w i s e ,w ea r et h ef i r s tt o
document the prevalence of coinfection of GBS and HR-
HPV in negative cytology (including RCC and ASCUS).
However, it remains uncertain that GBS may be an
independent factor or cofactor for HPV in the develop-
ment of cervical intraepithelial neoplasm. For identifica-
tion of its cofactor, novel immune evasion strategies and
the analysis of their functions in the context of viral and
bacterial infections should be required in further studies.
We compared high-throughput HPV detection meth-
ods in the present study, and found that discrepancies
with direct sequencing were observed only in 10.6%.
The microarray (DNA chip) method also resulted in a
significant number of false negative results. Analysis of
25discordant samples showed that multiplex PCR-HPV
method exhibited the highest sensitivity, positive predic-
tive value, and accuracy. However, each HPV detection
method covered different genotypes, and different typing
or grouping methods were used to present the data. For
example, the relatively low sensitivity of HC2 may be
due to its inability to detect LR genotypes, and its lower
positive predictive values and accuracy may be due to
limitations in detecting individual genotypes, and thus,
multiple infections.
Conclusions
In conclusion, asymptomatic women of reproductive age
with negative cytologic findings had a high frequency of
infection with GV, UU, GBS, and MH. Most HPV infec-
tions were not associated with any specific STI patho-
gen; however, LR-HPV infection correlated with CT
infection, and HR-HPV with GBS infection. In terms of
sensitivity and prediction value, multiplex PCR yielded
data most similar to that of DNA microarray.
Short Summary
Two hundred thirty-eight asymptomatic women of
reproductive age with negative cytology had high fre-
quency of sexually-transmitted infection (96.6%), and
24.4% had HPV.
Additional material
Additional file 1: Summarized data of target organisms, target
genes, accession numbers, and the expected amplicon sizes. Primers
were designed such amplicon sizes differed sufficiently to be
distinguished from each other; they ranged from 212 bp (UU)t o6 3 5b p
(CG) and the internal control was 981 bp.
Figure 2 ROC curve to detect HPV using multiplex-PCR, HC2,
and DNA microarray. ROC curve areas and 95% confidence
intervals between each of the three different methods are shown.
Table 3 Efficacy of multiplex-HPV PCR, HC2, and Chip, based on direct sequencing
True Positive True Negative False Positive False Negative HPV-all- Negative
PCR 48 175 5 7 235
HC2 45 173 6 9 233
Chip 47 176 4 8 235
Sensitivity Sensitivity-l Sensitivity-u Specificity Specificity-l Specificity-u AUC
PCR 87.2727 78.4646 96.0808 97.2222 94.8214 99.6230 0.922
HC2 83.3333 73.3932 93.2735 96.6480 94.0113 99.2848 0.900
Chip 85.4545 76.1369 94.7722 97.7778 95.6243 99.9312 0.916
PPV PPV-l PPV-u NPV NPV-l NPV-u Accuracy
PCR 90.5660 82.6965 98.4356 96.1538 93.3599 98.9478 94.8936
HC2 88.2353 79.3926 97.0779 95.0549 91.9051 98.2048 93.5622
Chip 92.1569 84.7782 99.5356 95.6522 92.7055 98.5988 94.8936
-l: lower limit of 95% confidence interval, -u: upper limit of 95% confidence interval.
AUC: area under the curve.
PPV: positive predictive value,
NPV: negative predictive value.
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